Metastatic extramammary Paget’s disease successfully treated by trastuzumab deruxtecan: a rare case report - Takeaways - MDSpire

Metastatic extramammary Paget’s disease successfully treated by trastuzumab deruxtecan: a rare case report

  • By

  • Lien-Ping Chou

  • Ming-Yang Lee

  • Chien-Liang Fang

  • Chun-Liang Tung

  • I-Li Lin

  • Cheng-Huang Shen

  • June 24, 2026

  • 0 min

Share

  • 1

    Metastatic extramammary Paget’s disease (mEMPD) is a rare cancer with a poor prognosis, particularly in cases with lymph node or visceral metastases.

  • 2

    Approximately 40% of mEMPD cases overexpress the Her2/neu protein, making it a significant target for precision-based systemic treatment.

  • 3

    A 73-year-old man with mEMPD showed partial response to trastuzumab deruxtecan after initial treatment with trastuzumab and pembrolizumab failed.

  • 4

    Next-generation sequencing revealed a high tumor mutation burden and mutations in ERBBR2, PIK3CA, and PTEN in the patient's tumor.

  • 5

    HER2-targeted therapies, including trastuzumab-docetaxel and T-DM1, demonstrate high efficacy in treating mEMPD.

Original Source(s)

Metastatic extramammary Paget’s disease successfully treated by trastuzumab deruxtecan: a rare case report

  • by Lien-Ping Chou, Ming-Yang Lee, Chien-Liang Fang, Chun-Liang Tung, I-Li Lin, Cheng-Huang Shen

  • June 24, 2026

Related Content

Next-generation CAR-T engineering for colorectal cancer: integrating targets, tumor microenvironment barriers, and emerging strategies

The mechanism of action, clinical significance, and research progress of tumor antigen-specific T cells in the treatment of HCC

The impact of the large B-cell lymphoma tumor microenvironment on efficacy of CD19-directed CAR-T immunotherapy